A preclinical-stage biopharma firm with a significant cash-on-cash balance pursuing high-risk, high-reward drug candidates while reporting minimal commercial revenue in recent years.
Investors may view the current stock as a deep-value speculative play on potential clinical trial readouts or strategic partnerships that could revalue the entire balance sheet, supported by a healthy $10.7M cash buffer remaining after recent expenditures.
The revenue has collapsed from $10.4M in 2022 to just $0.2M in 2025, and with a retained earnings deficit of over $600M and negative operating cash flow, the company faces an imminent liquidity crisis if it cannot secure additional capital or generate product sales soon.
aTYR Pharma Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for rare diseases and oncology, currently operating within the competitive small-cap pharmaceutical sector.
Despite a massive $66.0M inflow from financing activities last year, the company recorded a net loss of $74.1M driven primarily by $60.2M in research and development expenses and $17.6M in general and administrative costs, resulting in a significant reduction in cash and equivalents to $13.0M.
The biotechnology industry is characterized by high volatility where companies often trade based on pipeline milestones rather than current earnings, making early-stage firms like aTYR particularly sensitive to regulatory outcomes and capital market conditions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $10.4M | $353.0K | $235.0K | $190.0K |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $10.4M | $353.0K | $235.0K | $190.0K |
| Operating Expenses | $56.8M | $55.3M | $68.1M | $77.8M |
| Operating Income | $-46.4M | $-54.9M | $-67.9M | $-77.6M |
| R&D | $42.8M | $42.3M | $54.4M | $60.2M |
| G&A | $14.0M | $13.0M | $13.8M | $17.6M |
| Stock-Based Comp | $2.2M | $2.6M | $3.0M | $5.0M |
| D&A | $232.0K | $592.0K | $708.0K | $664.0K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $1.1M | $4.5M | $3.9M | $3.5M |
| Pre-Tax Income | $-45.3M | $-50.4M | $-64.0M | $-74.1M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-45.3M | $-50.4M | $-64.0M | $-74.1M |
| Discontinued Ops | $-3.0K | $-2.0K | $0 | $0 |
| Net Income | $-45.3M | $-50.4M | $-64.0M | $-74.1M |
| Minority Interest | $-5.0K | $-8.0K | $1.0K | $-5.0K |
| Net to Common | $-45.3M | $-50.4M | $-64.0M | $-74.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $80.9M | $103.0M | $82.0M | $80.2M |
| Cash & Equivalents | $10.0M | $22.5M | $11.1M | $10.7M |
| Other Current Assets | $70.9M | $80.4M | $70.9M | $69.5M |
| Long-Term Assets | $14.9M | $17.7M | $14.9M | $12.8M |
| PP&E (Net) | $3.1M | $5.5M | $4.8M | $4.3M |
| Operating Leases | $7.2M | $6.7M | $5.8M | $5.5M |
| Other LT Assets | $4.6M | $5.4M | $4.2M | $3.0M |
| Total Assets | $95.8M | $120.7M | $96.8M | $93.0M |
| Current Liabilities | $13.9M | $16.4M | $15.0M | $15.1M |
| Accounts Payable | $3.1M | $3.5M | $4.3M | $3.9M |
| Current Leases | $630.0K | $831.0K | $711.0K | $836.0K |
| Other Current Liab | $264.0K | $497.0K | $541.0K | $630.0K |
| Long-Term Liabilities | $10.6M | $13.8M | $12.0M | $10.6M |
| LT Operating Leases | $9.6M | $12.3M | $11.1M | $10.3M |
| Other LT Liab | $1.0M | $1.4M | $887.0K | $259.0K |
| Total Liabilities | $24.5M | $30.2M | $27.0M | $25.7M |
| Shareholders' Equity | $71.3M | $90.5M | $69.8M | $67.3M |
| Paid-In Capital | $489.5M | $558.7M | $602.0M | $673.6M |
| Retained Earnings | $-417.6M | $-468.0M | $-532.0M | $-606.2M |
| AOCI | $-433.0K | $-74.0K | $-40.0K | $-8.0K |
| Total L&E | $95.8M | $120.7M | $96.8M | $93.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-45.3M | $-50.4M | $-64.0M | $-74.1M |
| Non-Cash Adjustments | $-15.1M | $21.5M | $-8.7M | $21.1M |
| Working Capital Changes | $18.5M | $-4.3M | $3.6M | $-8.9M |
| Cash from Operations | $-41.9M | $-33.2M | $-69.1M | $-62.0M |
| Capital Expenditures | $1.6M | $4.2M | $65.0K | $77.0K |
| Cash from Investing | $47.2M | $-20.1M | $17.2M | $-5.1M |
| Cash from Financing | $5.5M | $66.2M | $39.9M | $66.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $10.8M | $12.9M | $-12.0M | $-1.0M |
| Beginning Cash | $2.3M | $13.1M | $26.0M | $14.0M |
| Ending Cash | $13.1M | $26.0M | $14.0M | $13.0M |
The company operates primarily through its core biopharmaceutical discovery segment targeting rare disease indications and oncology markets, with current financials reflecting pre-commercial activities and substantial investment in research and development rather than diversified product lines.
Complete dependence on future regulatory approvals from the FDA or EMA given zero commercial revenue, substantial burn rate exacerbated by declining cash reserves relative to operational needs, and the inherent high failure rate of early-stage biotechnology development pipelines.
Access to novel proprietary drug candidates with potential for blockbuster sales upon approval, a specialized team of scientific experts in rare disease mechanisms, and significant paid-in capital providing runway for continued R&D execution without immediate revenue pressure.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.